Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age
Public ClinicalTrials.gov record NCT05992935. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age
Study identification
- NCT ID
- NCT05992935
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Enrollment
- 1,407 participants
Conditions and interventions
Conditions
Interventions
- mRNA-1403 Biological
- mRNA-1405 Biological
- Placebo Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 24, 2023
- Primary completion
- Sep 21, 2026
- Completion
- Sep 21, 2026
- Last update posted
- Apr 2, 2026
2023 – 2026
United States locations
- U.S. sites
- 14
- U.S. states
- 13
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| ARK Clinical Research, LLC | Long Beach | California | 90815 | — |
| Tekton Research, Inc - Longmont Center | Longmont | Colorado | 80501 | — |
| Research Centers of America | Hollywood | Florida | 33024 | — |
| Accel Research Sites Network | Decatur | Georgia | 30030 | — |
| Velocity Clinical Research - Boise | Meridian | Idaho | 83642 | — |
| Optimal Research | Peoria | Illinois | 61614 | — |
| Velocity Clinical Research | Sioux City | Iowa | 51106 | — |
| Johnson County Clin-Trials (JCCT) | Lenexa | Kansas | 66219 | — |
| Velocity Clinical Research | Rockville | Maryland | 20854 | — |
| Velocity Clinical Research | Norfolk | Nebraska | 68701 | — |
| Velocity Clinical Research | Omaha | Nebraska | 68134 | — |
| Rochester Clinical Research, Inc | Rochester | New York | 14609 | — |
| Epic Medical Research, LLC | Red Oak | Texas | 75154 | — |
| JBR Clinical Research | Salt Lake City | Utah | 84107 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05992935, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 2, 2026 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05992935 live on ClinicalTrials.gov.